In patients who have pneumonitis related to ALK inhibitor therapy, is it possible to rechallenge patients with the same drug or a different ALK inhibitor?   

Lung toxicity in patients treated with ALK TKIs is a rare event, occurring in about 1-2% of patients, but can be serious and life threatening. Ceritinib may be associated with slightly less pulmonary adverse events (around 1%), while crizotinib, alectinib and lorlatinib are associated with pulmonary...